• Daratumumab-based induction/consolidation and maintenance resulted in the deepest and most durable MRD negativity, leading to superior PFS.

  • Daratumumab maintenance provided PFS benefit vs observation, regardless of MRD status or previous induction/consolidation therapy.

Subjects:
Clinical Trials and Observations, Lymphoid Neoplasia, Multiple Myeloma
Abstract

Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with daratumumab maintenance vs observation in transplant-eligible, newly diagnosed multiple myeloma. Here, we present long-term MRD status and PFS outcomes after a median follow-up of 80.1 months. Patients were randomly assigned (1:1) to daratumumab plus VTd (D-VTd) or VTd induction/consolidation; patients remaining on study were rerandomized to daratumumab maintenance or observation for ≤2 years. MRD status was assessed at predefined time points during each study phase. D-VTd improved overall MRD-negativity rates (10–5) after induction (34.6% vs 23.1%) and consolidation (63.7% vs 43.7%) and provided PFS benefit, regardless of postinduction MRD status, vs VTd alone. Daratumumab maintenance improved overall MRD-negativity rates over observation, regardless of induction/consolidation treatment (D-VTd/daratumumab vs D-VTd/observation, 10–5 [77.3% vs 70.7%] and 10–6 [60.7% vs 52.0%]; VTd/daratumumab vs VTd/observation, 10–5 [70.9% vs 51.2%] and 10–6 [48.4% vs 30.7%]) and improved MRD-negativity rates, regardless of risk status, as defined by cytogenetic abnormalities or the revised International Staging System score. Furthermore, daratumumab maintenance provided PFS benefit vs observation, regardless of induction/consolidation treatment and postconsolidation MRD status. D-VTd followed by daratumumab maintenance consistently produced the highest landmark, cumulative, and sustained MRD-negativity rates (10–5 and 10–6), translating to superior long-term PFS outcomes. These results demonstrate that daratumumab-based induction/consolidation followed by daratumumab maintenance resulted in the deepest and most durable MRD negativity, leading to superior PFS outcomes. This trial was registered at www.clinicaltrials.gov as #NCT02541383.

Subjects:
Clinical Trials and Observations, Lymphoid Neoplasia, Multiple Myeloma
1.
de Weers
M
,
Tai
YT
,
van der Veer
MS
, et al.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
.
J Immunol
.
2011
;
186
(
3
):
1840
-
1848
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Lammerts van Bueren
J
,
Jakobs
D
,
Kaldenhoven
N
, et al.
Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79
.
Blood
.
2014
;
124
(
21
):
3474
.
Google Scholar
Crossref
Search ADS
 
3.
Overdijk
MB
,
Verploegen
S
,
Bögels
M
, et al.
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
.
MAbs
.
2015
;
7
(
2
):
311
-
321
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Overdijk
MB
,
Jansen
JH
,
Nederend
M
, et al.
The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking
.
J Immunol
.
2016
;
197
(
3
):
807
-
813
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Krejcik
J
,
Casneuf
T
,
Nijhof
IS
, et al.
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
.
Blood
.
2016
;
128
(
3
):
384
-
394
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Adams
HC III
,
Stevenaert
F
,
Krejcik
J
, et al.
High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action
.
Cytometry A
.
2019
;
95
(
3
):
279
-
289
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Casneuf
T
,
Adams
HC
,
van de Donk
NWCJ
, et al.
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
.
Leukemia
.
2021
;
35
(
2
):
573
-
584
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Mateos
MV
,
Dimopoulos
MA
,
Cavo
M
, et al.
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
.
N Engl J Med
.
2018
;
378
(
6
):
518
-
528
.
Google Scholar
Crossref
Search ADS
PubMed
 
9.
Mateos
MV
,
Cavo
M
,
Blade
J
, et al.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
.
Lancet
.
2020
;
395
(
10218
):
132
-
141
.
Google Scholar
Crossref
Search ADS
PubMed
 
10.
Facon
T
,
Kumar
S
,
Plesner
T
, et al.
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
.
N Engl J Med
.
2019
;
380
(
22
):
2104
-
2115
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Facon
T
,
Kumar
SK
,
Plesner
T
, et al.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
.
Lancet Oncol
.
2021
;
22
(
11
):
1582
-
1596
.
Google Scholar
Crossref
Search ADS
PubMed
 
12.
Moreau
P
,
Attal
M
,
Hulin
C
, et al.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
.
Lancet
.
2019
;
394
(
10192
):
29
-
38
.
Google Scholar
Crossref
Search ADS
PubMed
 
13.
Moreau
P
,
Hulin
C
,
Perrot
A
, et al.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
.
Lancet Oncol
.
2021
;
22
(
10
):
1378
-
1390
.
Google Scholar
Crossref
Search ADS
PubMed
 
14.
Moreau
P
,
Hulin
C
,
Perrot
A
, et al.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
.
Lancet Oncol
.
2024
;
25
(
8
):
1003
-
1014
.
Google Scholar
Crossref
Search ADS
PubMed
 
15.
Sonneveld
P
,
Dimopoulos
MA
,
Boccadoro
M
, et al.
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma
.
N Engl J Med
.
2024
;
390
(
4
):
301
-
313
.
Google Scholar
Crossref
Search ADS
PubMed
 
16.
DARZALEX® (daratumumab) injection. Package insert
.
Janssen Biotech, Inc
;
2024
.
17.
European Medicines Agency
.
DARZALEX 20 mg/mL concentrate for solution for infusion. Summary of product characteristics
. Accessed 29 October 2024. https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf.
18.
Landgren
O
,
Prior
TJ
,
Masterson
T
, et al.
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
.
Blood
.
2024
;
144
(
4
):
359
-
367
.
Google Scholar
Crossref
Search ADS
PubMed
 
19.
Lahuerta
JJ
,
Paiva
B
,
Vidriales
MB
, et al.
Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials
.
J Clin Oncol
.
2017
;
35
(
25
):
2900
-
2910
.
Google Scholar
Crossref
Search ADS
PubMed
 
20.
Cavo
M
,
San-Miguel
J
,
Usmani
SZ
, et al.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
.
Blood
.
2022
;
139
(
6
):
835
-
844
.
Google Scholar
Crossref
Search ADS
PubMed
 
21.
San-Miguel
J
,
Avet-Loiseau
H
,
Paiva
B
, et al.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
.
Blood
.
2022
;
139
(
4
):
492
-
501
.
Google Scholar
Crossref
Search ADS
PubMed
 
22.
Munshi
NC
,
Avet-Loiseau
H
,
Rawstron
AC
, et al.
Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis
.
JAMA Oncol
.
2017
;
3
(
1
):
28
-
35
.
Google Scholar
Crossref
Search ADS
PubMed
 
23.
Munshi
NC
,
Avet-Loiseau
H
,
Anderson
KC
, et al.
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma
.
Blood Adv
.
2020
;
4
(
23
):
5988
-
5999
.
Google Scholar
Crossref
Search ADS
PubMed
 
24.
Landgren
O
,
Devlin
S
,
Boulad
M
,
Mailankody
S
.
Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
.
Bone Marrow Transpl
.
2016
;
51
(
12
):
1565
-
1568
.
Google Scholar
Crossref
Search ADS
 
25.
Perrot
A
,
Lauwers-Cances
V
,
Corre
J
, et al.
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
.
Blood
.
2018
;
132
(
23
):
2456
-
2464
.
Google Scholar
Crossref
Search ADS
PubMed
 
26.
International Myeloma Foundation
.
A historic turning point: ODAC unanimously votes in favor of MRD testing as an early endpoint in myeloma clinical trials to support accelerated approvals of new treatments
. Accessed 29 October 2024. https://www.myeloma.org/blog/dr-duries/odac-unanimously-in-favor-mrd-testing-early-endpoint-myeloma.
27.
Engelhardt
M
,
Kortüm
KM
,
Goldschmidt
H
,
Merz
M
.
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
.
Haematologica
.
2024
;
109
(
8
):
2420
-
2435
.
Google Scholar
PubMed
 
28.
Rodriguez-Otero
P
,
Paiva
B
,
San-Miguel
JF
.
Roadmap to cure multiple myeloma
.
Cancer Treat Rev
.
2021
;
100
:
102284
.
Google Scholar
Crossref
Search ADS
PubMed
 
29.
International Myeloma Foundation
.
A deeper understanding of ‘cure’ in multiple myeloma
. Accessed 29 October 2024. https://www.myeloma.org/blog/dr-duries/deeper-understanding-of-cure-in-myeloma#:∼:text=In%20order%20to%20achieve%20a,diseases%20or%20illnesses)%20are%20considered.
30.
Caro
J
,
Al Hadidi
S
,
Usmani
S
,
Yee
AJ
,
Raje
N
,
Davies
FE
.
How to treat high-risk myeloma at diagnosis and relapse
.
Am Soc Clin Oncol Educ Book
.
2021
;
41
:
291
-
309
.
Google Scholar
PubMed
 
31.
Rajkumar
SV
,
Dimopoulos
MA
,
Palumbo
A
, et al.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
.
Lancet Oncol
.
2014
;
15
(
12
):
e538
-
e548
.
Google Scholar
Crossref
Search ADS
PubMed
 
32.
Durie
BGM
,
Harousseau
JL
,
Miguel
JS
, et al.
International uniform response criteria for multiple myeloma
.
Leukemia
.
2006
;
20
(
9
):
1467
-
1473
.
Google Scholar
Crossref
Search ADS
PubMed
 
33.
Rajkumar
SV
,
Harousseau
JL
,
Durie
B
, et al.
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
.
Blood
.
2011
;
117
(
18
):
4691
-
4695
.
Google Scholar
Crossref
Search ADS
PubMed
 
34.
Flores-Montero
J
,
Sanoja-Flores
L
,
Paiva
B
, et al.
Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
.
Leukemia
.
2017
;
31
(
10
):
2094
-
2103
.
Google Scholar
Crossref
Search ADS
PubMed
 
35.
Voorhees
PM
,
Kaufman
JL
,
Laubach
J
, et al.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
.
Blood
.
2020
;
136
(
8
):
936
-
945
.
Google Scholar
Crossref
Search ADS
PubMed
 
36.
Laubach
J
,
Kaufman
JL
,
Sborov
DW
, et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of GRIFFIN after 24 months of maintenance. Paper presented at:.
American Society of Hematology Annual Meeting and Exposition
;
11-14 December 2021
. Atlanta, GA.
37.
Voorhees
PM
,
Sborov
DW
,
Laubach
J
, et al.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
.
Lancet Haematol
.
2023
;
10
(
10
):
e825
-
e837
.
Google Scholar
Crossref
Search ADS
PubMed
 
38.
Sonneveld
P
,
Dimopoulos
MA
,
Boccadoro
M
, et al.
Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd alone in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT): primary results of the PERSEUS trial [abstract]
.
Blood
.
2023
;
142
(
suppl 2
):
LBA-1
.
Google Scholar
 
39.
Rodríguez-Otero
P
,
Moreau
P
,
Dimopoulos
MA
, et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. Paper presented at:.
American Society of Clinical Oncology Annual Meeting
;
31 May to 4 June 2024
. Chicago, IL.
40.
Badros
AZ
,
Foster
L
,
Anderson
LD
, et al.
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
.
Blood
.
2025
;
145
(
3
):
300
-
310
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
Sign in via your Institution